Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Pasireotide in Advanced HCC
NCT01488487Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Dec 2011
- Primary completion
- Mar 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus, pasireotide LAR in hepatocellular carcinoma (HCC), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Dec 2011; status: completed.
02
Drugs
everolimuspasireotide LAR
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01488487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01488487.